Volume 30, Issue 140 (May & June 2022)                   J Adv Med Biomed Res 2022, 30(140): 263-268 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alishiri G H, Ataee R A, Ramezanpour M, Chaleshi D, Rahmanian E. Correlation between Serum Levels of Calprotectin with Disease Activity in Rheumatoid Arthritis Patients. J Adv Med Biomed Res 2022; 30 (140) :263-268
URL: http://journal.zums.ac.ir/article-1-6636-en.html
Correlation between Serum Levels of Calprotectin with Disease Activity in Rheumatoid Arthritis Patients
Gholam Hossein Alishiri1 , Ramezan Ali Ataee2 , Mahsa Ramezanpour3 , Danial Chaleshi4 , Ehsan Rahmanian * 5
1- Dept. of Rheumatology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
2- Dept. of Medical Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- Dept.of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran
4- Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
5- Dept.of Rheumatology, School of Hormozgan University of Medical Sciences, Bandar-e Abbas, Iran , drrahmanianehsan@yahoo.com
Abstract:   (79378 Views)

Background and Objective: Rheumatoid arthritis (RA) is an autoimmune disease defined by chronic synovitis and progressive joint destruction. This study investigated calprotectin as a serological marker in the hope of establishing an adequate means of diagnosing RA and following up on patients.
Materials and Methods: This cross-sectional study included 32 RA patients who were referred to the rheumatology clinic of Baqiyatallah Hospital (Tehran, Iran) from 2019 to 2020. clinical examinations and requested laboratory tests was performed. The final visit was placed after a year with the same method as the initial visit. Disease activity was assessed by Disease Activity Score 28 (DAS-28) for 28 joints which is assessable by ESR or CRP and data were analyzed by SPSS 20 version.
Results: Changes over time were significant in both (P=0.00 and P=0.00), and a significant relationship was found between the quantitative scores of the two forms of DAS-28 (P<0.000). Calprotectin did not show any significant correlation with either form of the DAS-28 quantitatively. Ahead of logistic regression analysis on the after one-year C-reactive protein based DAS-28 data, patients with cured disease or low disease activity were combined into one group. Accordingly, calprotectin was able to predict RA activity level to some extent (P=0.06), though a more efficient prediction was achieved when erythrocyte sedimentation rate and calprotectin were applied together (P=0.03).
Conclusion: ESR and calprotectin did not show good power in predicting disease activity individually but they could have significantly high prediction potency combined.

Keywords: Rheumatoid arthritis, Calprotectin, Disease activity
Full-Text [PDF 684 kb]   (41654 Downloads) |   |   Full-Text (HTML)  (1309 Views)  

✅ ESR and calprotectin did not show good power in predicting disease activity individually but they could have significantly high prediction potency combined.


Type of Study: Original Article | Subject: Clinical medicine
Received: 2021/07/23 | Accepted: 2022/01/18 | Published: 2022/04/1
References
1. Opeć-Mędrek M, Widuchowska M, Kucharz EJ. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54(6):306-9. [DOI:10.5114/reum.2016.64907] [PMID] [PMCID]
2. Cesaro A, Anceriz N, Plante A, Pagé N, Tardif MR, Tessier PA. An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis. PLoS ONE. 2012;7(9). [DOI:10.1371/journal.pone.0045478] [PMID] [PMCID]
3. van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Practice and Research: Clin Rheumatol. 2018;32(2):174-87. [DOI:10.1016/j.berh.2018.10.005] [PMID]
4. Farng E, Friedrich JB. Laboratory diagnosis of rheumatoid arthritis. J Hand Surg. 2011;36(5):926-7. [DOI:10.1016/j.jhsa.2011.01.036] [PMID]
5. Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880 [DOI:10.3390/cells9040880] [PMID] [PMCID]
6. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA . 2018;320(13):1360-72. [DOI:10.1001/jama.2018.13103] [PMID]
7. Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: A systematic review. J Rheumatol. 2015;42(5):760-70. [DOI:10.3899/jrheum.140628] [PMID]
8. Mansour HE, Abdullrhman MA, Mobasher SA, et al. Serum calprotectin in rheumatoid arthritis: A promising diagnostic marker, how far is it related to activity and sonographic findings? J Med Ultrasound. 2017;25(1):40-6. Available from: http://dx.doi.org/10.1016/j.jmu.2016.11.001 [DOI:10.1016/j.jmu.2016.11.001] [PMID] [PMCID]
9. Fleischmann RM, Van Der Heijde D, Gardiner P V., Szumski A, Marshall L, Bananis E. DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open. 2017;3(1):2-6. [DOI:10.1136/rmdopen-2016-000382] [PMID] [PMCID]
10. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheumatic Disease. 2007;66(3):407-9. [DOI:10.1136/ard.2006.054205] [PMID] [PMCID]
11. Tamhane A, Redden DT, McGwin G, et al. Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. J Rheumatol. 2013;40(11):1812-22. [DOI:10.3899/jrheum.121225] [PMID] [PMCID]
12. Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol. 2009;36(8):1606-10. [DOI:10.3899/jrheum.081188] [PMID]
13. Hensor EMA, Emery P, Bingham SJ, et al. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): Can they be reduced? Rheumatol. 2010;49(8):1521-9. Available from: [DOI:10.1093/rheumatology/keq117] [PMID]
14. Berntzen HB, Ölmez Ü, Fagerhol MK, Munthe E. The leukocyte protein l1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scandinavian J Rheumatol. 1991;20(2):74-82. [DOI:10.3109/03009749109165280] [PMID]
15. Hammer HB, Ødeg̊ard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheumatic Disease. 2007;66(8):1093-7. [DOI:10.1136/ard.2006.064741] [PMID] [PMCID]
16. Brun JG, Haga HJ, Boe E, et al. Calprotectin in patients with rheumatoid arthritis: Relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992;19(6):859-62.
17. García-Arias M, Pascual-Salcedo D, Ramiro S, , et al. Calprotectin in rheumatoid arthritis: Association with disease activity in a cross-sectional and a longitudinal cohort. Molec Diag Ther. 2013;17(1):49-56. [DOI:10.1007/s40291-013-0016-9] [PMID]
18. Hurnakova J, Zavada J, Hanova P, et al. Serum calprotectin (S100A8/9): An independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):252. [DOI:10.1186/s13075-015-0764-5] [PMID] [PMCID]
19. Nordal HH, Brun JG, Hordvik M, Eidsheim M, Jonsson R, Halse AK. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. Scandinavian J Rheumatol. 2016;45(4):274-81. [DOI:10.3109/03009742.2015.1107128] [PMID]
20. Andrés Cerezo L, Mann H, Pecha O, Pleštilová L, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122. [DOI:10.1186/ar3426] [PMID] [PMCID]
21. Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scandinavian J Rheumatol. 2008;37(3):179-82. [DOI:10.1080/03009740701874451] [PMID]
22. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA. Clinical Rheumatology. 2007 Feb;26(2):201-4. [DOI:10.1007/s10067-006-0275-5] [PMID]
23. Wang Q, Chen W, Lin J. The Role of calprotectin in rheumatoid arthritis. J Translat internal Med. 2019;7(4):126-31. [DOI:10.2478/jtim-2019-0026] [PMID] [PMCID]
24. Romand X, Bernardy C, Nguyen MVC, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691-8. [DOI:10.1016/j.jbspin.2019.01.003] [PMID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb